BUZZ-Transition Therapeutics Inc: Alzheimer drug effective in sub-group

Thu Oct 15, 2015 8:36am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Canadian drug developer's shares up nearly 17 pct premarket

** Company says analysis shows the drug ELND005 was effective in reducing severe agitation and aggression in Alzheimer's patients

** Large study in June failed to hit main goal of reducing moderate to severe agitation and aggression in patients, pushing shares down as much as 20 pct that day

** Company says to discuss potential late-stage study with the U.S. FDA

** Up to Wednesday's close, stock had fallen about 20 pct since the company reported top-line data from the study